Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Capecitabine in Relapsed/Refractory Carcinoma of Unknown Primary Site
NCT00193609Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2004
- Primary completion
- Apr 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in carcinoma of unknown primary (CUP), sponsored by SCRI Development Innovations. Primary endpoint: Progression Free Survival at 18 months. Started Sep 2004; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00193609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193609.